New expert group agrees plan to analyse full data on oseltamivirBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f4022 (Published 20 June 2013) Cite this as: BMJ 2013;346:f4022
- Zosia Kmietowicz
A multidisciplinary group of scientific experts has developed a plan to analyse data on the influenza drug oseltamivir (Tamiflu) that they hope will provide answers to whether current guidelines on its use need to be amended.
The Multiparty Group for Advice on Science (MUGAS) met for the first time in Brussels on 18 June. It was initiated by four academics: Ab Osterhaus, head of the Institute of Virology at Erasmus MC University in Rotterdam, who also works as a scientific adviser to Roche; Arnold Monto, professor of epidemiology at the University of Michigan; Menno de Jong, of Amsterdam’s Institute for Global Health and Development; and Rich Whitley, from the University …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.